Tibolone Improves Myocardial Perfusion in Postmenopausal Women With Ischemic Heart Disease An Open-Label Exploratory Pilot Study by Campisi, Roxana et al.
T
P
A
R
A
B
S
g
b
t
i
a
b
h
i
(
(
t
m
p
o
w
s
M
S
w
c
s
P
p
a
Journal of the American College of Cardiology Vol. 47, No. 3, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Pibolone Improves Myocardial Perfusion in
ostmenopausal Women With Ischemic Heart Disease
n Open-Label Exploratory Pilot Study
oxana Campisi, MD,* Jorge Camilletti, MD,* Aníbal Mele, MD,* Juan Erriest, MD,* Pablo Pedroni, MD,*
riel Guiglioni, MD†
uenos Aires, Argentina
OBJECTIVES We sought to determine the effect of tibolone on myocardial perfusion in postmenopausal
women with ischemic heart disease.
BACKGROUND Tibolone is a steroid that relieves climacteric symptoms and prevents osteoporosis. Recent
studies have suggested a cardioprotective effect of this compound. However, its role on
myocardial perfusion remains uncertain.
METHODS Single-photon emission computed tomography myocardial perfusion imaging was performed
in 26 postmenopausal women. Patients were randomly assigned to tibolone for six months
(treatment group) or to usual care (control group). All women underwent cardiac imaging at
baseline and at six months.
RESULTS Mean stress perfusion defect (summed stress score) was moderate and did not differ between
the two groups (8  3 vs. 9  4; p  NS). Summed difference score also was similar for both
groups (7  3 vs. 8  3; p  NS). The six-month study reveled that summed stress and
summed difference scores significantly improved in the treatment group (to 3  3 and to
2  2; p  0.001) whereas it remained unchanged for control patients (to 10  4 and to
8  2; p  NS).
CONCLUSIONS In postmenopausal women with ischemic heart disease, six months of therapy with tibolone
significantly improved stress myocardial perfusion and the “amount of ischemia.” (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.033Coll Cardiol 2006;47:559–64) © 2006 by the American College of Cardiology Foundation
t
b
m
c
a
o
R
n
w
t
A
g
t
m
a
w
b
o
o
t
i
p
m
p
e
mpecific-activity steroids have the beneficial effects of estro-
en on bone and brain without the known increased risk for
reast cancer and endometrial hyperplasia observed in long-
erm users of estrogen. Tibolone, a specific-activity steroid,
s a synthetic compound that relieves climacteric symptoms
nd prevents osteoporosis (1).
Recent studies have reported that tibolone therapy might
e of benefit in the prevention of cardiovascular disease. In
ealthy postmenopausal women, tibolone tends toward
ncreased fibrinolysis and improves endothelial function
2,3). Interestingly, in women with coronary artery disease
CAD), it has been suggested that tibolone might attenuate
he ischemic burden (4). However, its role in modulating
yocardial perfusion remains uncertain. In this open-label
ilot study, the objective was therefore to evaluate the effects
f tibolone on myocardial perfusion in postmenopausal
omen with ischemic heart disease (IHD) as assessed by
ingle-photon emission computed tomography (SPECT).
ETHODS
tudy population and design. Twenty-six postmenopausal
omen not on hormone-replacement therapy referred for a
linically indicated SPECT myocardial perfusion study with
tress-induced perfusion defects were enrolled. All had cessa-
From the *Instituto de Cardiología La Plata and †Centro de Reproducción y
lanificación Familiar, Buenos Aires, Argentina. Dr. Campisi is the recipient of a
hysician-initiated research grant by Bristol-Myers Squibb.a
Manuscript received March 19, 2005; revised manuscript received July 14, 2005,
ccepted September 10, 2005.ion of menses of one year or longer, a normal mammogram,
reast and pelvic examinations, and pap test within six
onths of the study. Patients with recent history of myo-
ardial infarction (1 month), severe aortic stenosis (as
ssessed by echocardiography), known or suspected cancer,
r undiagnosed abnormal vaginal bleeding were excluded.
This study is a prospective randomized open-label study.
andomization was performed using a table with random
umbers. After their baseline SPECT scans, all patients
ere assigned randomly to usual care (control group) or to
ibolone (Paraclim, ELEA Pharmaceuticals, Buenos Aires,
rgentina) at 1.25 mg/day for six months (treatment
roup). Vaginal ultrasound was performed on the subjects
he day before they started tibolone therapy and then at six
onths. All women underwent SPECT imaging at baseline
nd at six months. Beta-blockers and calcium antagonists
ere stopped four days before each scan and caffeine 24 h
efore the test in all patients.
Patients performed a symptom-limited exercise stress test
n both sessions. Dipyridamole was infused in one patient
f each group (because of poor exercise tolerance in one and
he development of left bundle brunch block at peak exercise
n the other patient). In all but one patient (because of a
hysical inability to exercise) the stress testing modality was
aintained for the second SPECT scan. Rate-pressure
roduct (RPP) was calculated in the patients that underwent
xercise stress testing.
Coronary angiography was performed within 6  4
onths of the baseline scan. Significant CAD was defineds 50% diameter narrowing of a major coronary artery or
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Tibolone and Myocardial Perfusion February 7, 2006:559–64ne of its major branches on visual analysis. The study was
pproved by the Research Subjects Review Board and the
nformed consent was performed for each woman.
ingle-photon emission computed tomography perfusion
maging and image analysis. Myocardial perfusion imag-
ng was performed using previously described same-day
tress-rest protocol. At peak exercise, 8 to 10 mCi of
9mtechnetium-sestamibi were injected and 25 to 35 mCi
or resting images. In the two patients that underwent
ipyridamole-hyperemia, 0.56 mg/kg were infused over the
ourse of 4 min. The acquisition SPECT was performed
sing a dual-head gamma camera over a 180° elliptical orbit.
ata were acquired in a 64  64 matrix for 60 projections
n a step and shoot format.
Consensus interpretation for myocardial perfusion data
ith visual over-reading by three readers was performed.
nblinded semiquantitative analysis was accomplished us-
ng the Cedars method (5). A summed stress score (SSS),
eflecting quantitative defect extent and severity, a summed
est score (SRS), and a summed difference score (SDS),
eflecting “amount of ischemia” were calculated. Differences
n summed perfusion scores from baseline to six-month
erfusion study were rated as previously reported (3 
improved,” 3 to 3  “no change,” 3  “worse”)
6). Resting images were gated and data were processed
ith QGS software (Cedars QGSTM program, Los An-
eles, California) (7).
To address a scan interpretation bias, we also performed
n automated quantitative analysis of the perfusion images
sing the CEqual software (Atlanta, Georgia) in all partic-
pants (8).
tatistical analysis. Continuous measures are expressed as
ean values  SD. Dichotomous variables are presented as
number or percentages. Comparisons within groups (at
aseline and at six months) were performed using the paired
tudent t test for continuous variables and Wilcoxon signed
ank test for ordinal variables. Comparisons between groups
ere performed using the Fisher exact test. Continuous
ariables were compared by unpaired Student t test. Ordinal
ariables were analyzed by Mann-Whitney rank sum test.
tatistical significance was accepted at a level of p  0.05.
ESULTS
tudy subjects. After randomization, 11 women were en-
Abbreviations and Acronyms
CAD  coronary artery disease
IHD  ischemic heart disease
NO  nitric oxide
RPP  rate-pressure product
SDS  summed difference score
SPECT  single-photon emission computed tomography
SRS  summed rest score
SSS  summed stress scoreolled in the treatment group and 15 in the control group.
*ne patient under tibolone was excluded because of vaginal
leeding. Thus, 10 patients comprised the treatment group.
one of the women exhibited endometrial hyperplasia after
ibolone treatment. Four women in the control group were
xcluded before the second scan (because of coronary
evascularization in two and failure of subsequent follow-up
n the other two participants). Thus, 11 women comprised
he control group. Table 1 shows the baseline characteristics
f the 21 women completing the study. Coronary angiog-
aphy was obtained in 16 participants. Significant CAD was
ound in all patients. Two women in each group underwent
PECT imaging for diagnosis of CAD. Table 2 shows
oncomitant medications taken at baseline. They were not
ifferent at six months for both groups. None of the 21
atients were revascularized before the second scan.
tress testing. In the treatment group, five patients exhib-
ted chest pain and two exhibited ST-segment depression
uring stress. At six months, four women exhibited chest
ain and one showed ST-segment depression during stress.
able 1. Baseline Characteristics of the 21 Postmenopausal
omen Completing the Study Protocol
Treatment Group
(n  10)
Control Grou
(n  11)
ge, yrs 63  11 67  7
uration of menopause, yrs 17  11 21  9
ody mass index, kg/m2 27.39  3.29 26.66  3.72
ypertension, n 8 (80%) 8 (73%)
iabetes, n 2 (20%) 3 (27%)
ypercholesterolemia, n 3 (30%) 4 (36%)
igarette smoking, n 1 (10%) 0
amily history of CAD, n 6 (60%) 6 (55%)
revious myocardial infarction, n 3 (30%) 4 (36%)
revious coronary bypass
surgery, n
0 1 (9%)
revious percutaneous coronary
intervention, n
2 (20%) 2 (18%)
oronary angiography, n 7 9
1  vessel disease 3 (42%) 3 (33%)
2  vessel disease 2 (29%) 3 (33%)
3  vessel disease 2 (29%) 3 (33%)
ndications for SPECT imaging
Chest pain or dyspnea, n 8 (80%) 9 (82%)
Asymptomatic with known
CAD, n
2 (20%) 2 (18%)
ll p  NS between groups.
CAD  coronary artery disease; SPECT  single-photon emission computed
omography.
able 2. Concomitant Medication Taken at Baseline
Treatment Group Control Group
spirin 10 9
eta-blockers 6 8
itrates 3 3
CE inhibitors 3 5
alcium channel blockers 6* 0
tatins 3 3
nsulin 0 1
ulfonylureas 1 0p  0.011 vs. control patients.
ACE  angiotensin-converting enzyme.
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February 7, 2006:559–64 Tibolone and Myocardial Perfusionn the control group, 4 of the 11 patients exhibited chest pain
nd ST-segment depression during stress. At six months, 3 of
he 11 patients exhibited chest pain and ST-segment depres-
ion (p  NS between the groups for both sessions). As
hown in Table 3, exercise-induced comparable increases in
eart rate, systolic blood pressure, and RPP in both groups
t baseline and at six months.
ingle-photon emission computed tomography myocar-
ial perfusion imaging. Average baseline SSS was moder-
te for both groups (Table 4). In the treatment group, the
ix-month study exhibited a significant decline to a probably
ormal-average score. SSS showed a significant reduction in
of the 10 postmenopausal women and remained un-
hanged in 1 patient (Fig. 1, Table 4). The SRS was
nchanged at six months in all women, but SDS was better
or 9 of the 10 women receiving tibolone (Fig. 2). An
xample is shown in Figure 3.
able 3. Results of the Exercise Stress Testing
Treatment G
Baseline
eart rate, beats/min
Rest 82  14
Exercise 144  16*
BP, mm Hg
Rest 142  18
Exercise 181  28*
eak RPP, beats/min  mm Hg 27,561  4,984
predicted heart rate 96  16
xercise duration, min 6.14  2.38
eak workload (METs) 6.23  2.14
p  0.00001 exercise vs. rest. At six months, no variables were significantly differen
RPP  rate-pressure product; SBP  systolic blood pressure.
able 4. Single-Photon Emission Tomography Myocardial
erfusion Imaging and Left Ventricular Function for the 21
ostmenopausal Women
Treatment Group Control Group
Baseline
6
Months Baseline
6
Months
core perfusion analysis
SSS 8  3 3  3*§ 9  4 10  4
SRS 1  2 1  2 2  3 2  3
SDS 7  3 2  2*§ 8  3 8  2
utomated quantitative
analysis
Extent (% LV
hypoperfusion)
17  6 7  7†‡ 15  7 16  7
Reversibility (% LV) 16  6 5  5†§ 12  3 13  5
esting LV function
(by gated SPECT)
LVEF (%) 66  8 67  10 66  8 70  7
LVEDV (ml) 68  19 75  21 76  30 63  11
LVESV (ml) 24  11 26  12 27  16 20  7
p  0.05 and †p  0.01 vs. baseline; ‡p  0.02 and §p  0.005 treatment group vs.
ontrols at six months.
LV  left ventricular; LVEF  left ventricular ejection fraction; LVEDV  left
entricular end-diastolic volume; LVESV left ventricular end-systolic volume; SDSw
ummed difference score; SPECT  single-photon emission computed tomography;
RS  summed rest score; SSS  summed stress score.In contrast, in the control group, the six-month study
howed that average SSS remained unchanged (Fig. 1,
able 4). The SSS was reduced in one patient and increased
n two patients, SRS was unchanged at six months for all
omen, and SDS was improved in one patient and worse in
nother patient. Automated quantitative analysis of the
mages showed similar results to that from the score
erfusion analysis in both groups (Table 4).
eft ventricular function. At baseline, mean left ventric-
lar ejection fraction and left ventricular volumes were
imilar for the two groups. These parameters remained
nchanged at six months (Table 4).
ISCUSSION
he major finding of the current study is that six months of
reatment with tibolone decreased the extent and severity of
yocardial perfusion abnormalities during stress and the
amount of ischemia” in postmenopausal women with IHD.
o the best of our knowledge, this is the first report using
PECT imaging that assessed the effect of tibolone on
yocardial perfusion in women with IHD.
Tibolone mainly is used for treating climacteric symp-
oms and for the prevention of osteoporosis. It displays
strogenic, progestogenic, or androgenic activity, depending
rimarily on the target tissue involved (9). Consequently,
his compound is considered a drug with tissue-specific
ctivity.
Experimental and clinical data have suggested that tibolone
as beneficial effects on the cardiovascular system. For exam-
le, tibolone, unlike estrogen, possesses anti-inflammatory
roperties and tends toward increased fibrinolysis (2). Further-
ore, in women with CAD, a single dose of 2.5 mg of
ibolone improved the time to onset of ST-segment depres-
ion and angina symptoms during exercise (4). In our study,
e did not observe such effect after six months of 1.25
g/day of treatment. One possible explanation is that a
ower dose of tibolone might be insufficient to detect a
eneficial effect on these parameters. Because our patients
Control Group
6 Months Baseline 6 Months
74  12 84  17 80  17
135  24* 142  22* 136  18*
141  25 135  14 137  19
177  29* 170  16* 174  21*
,428  6,046 25,671  3,680 23,585  4,742
93  16 100  11 96  13
6.24  2.32 5.23  1.53 5.33  1.33
6.24  1.92 4.98  0.96 5.00  1.76
een either group.roup
25ere late postmenopausal women, we selected the lowest
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Tibolone and Myocardial Perfusion February 7, 2006:559–64ose of tibolone with a proven clinical effect for treating
limacteric symptoms (10). We observed a significant im-
rovement in regional myocardial perfusion in women
reated with this dose. Importantly, the heart rate and RPP
chieved during stress were similar at baseline and after
ibolone therapy. Thus, our findings cannot be attributed to
ifferences in myocardial oxygen demand during exercise.
Estrogen withdrawal during menopause impairs coronary
ascular function and is associated with lower nitric oxide
NO) levels than those measured in the general population,
uggesting that endothelial dysfunction is involved (3).
onsistently, recent studies using positron emission tomog-
aphy have shown that postmenopausal women with risk
igure 1. Baseline summed stress score (SSS) was moderate for both grou
o a probably normal-average score, whereas it remained unchanged in coigure 2. Average summed difference score (SDS) was moderate for both groups
bserved in the control group.actors have impaired endothelial function (11,12). Estro-
en increases synthesis of NO by the vascular endothelium;
owever, estrogen administration did not reverse this ab-
ormality as assessed by positron emission tomography (11).
nimal studies have shown that tibolone activates the
strogen receptor and induces a similar percent increase in
O levels than estrogen in postmenopausal women (9).
ibolone may, therefore, have a favorable effect on the
ndothelium, which might suggest a cardioprotective effect
3). Despite the fact our study did not address the potential
echanism(s) by which tibolone improved myocardial perfu-
ion, it has recently reported that nuclear cardiology methods
an detect the effects of pharmacological interventions
the treatment group, the six-month study exhibited a significant decline
patients.ps. Inat baseline. It only was reduced in the treatment group. No changes were
F
h
t
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February 7, 2006:559–64 Tibolone and Myocardial Perfusionigure 3. Example of single-photon emission computed tomography images in a patient receiving treatment with tibolone. (A) At baseline, the short axis,
orizontal long axis, and vertical long axis show an extensive and severe reversible perfusion defect in the inferior and lateral walls. (B) Six months after
ibolone therapy, there is a significant improvement in the perfusion defects during stress.
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Tibolone and Myocardial Perfusion February 7, 2006:559–64argeting the vascular endothelium in individuals at risk for
r with IHD (12).
tudy limitations. We tested the possibility that our find-
ngs might have been attributed to a scan-interpretation
ias. However, reanalyses of the studies without knowledge
f their sequence and treatment allocation (data not shown) by
emiquantitative and automated quantitative analysis con-
rmed our findings in both groups. In addition, vasoactive
edications (beta-blockers and calcium antagonists) might
ave interfered with our findings. Because they were
topped for four days before each scan in both groups, it is
nlikely that their effect could have been affected our results.
onclusions. In postmenopausal women with IHD, six
onths of therapy with tibolone significantly improved
tress myocardial perfusion defects and the “amount of
schemia” as assessed by SPECT imaging. However, clinical
ecommendations must wait until larger studies are performed.
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